Editorial
Improving transparency of drug regulatory decisions
BMJ · 21.09.2026 · 394 · e100749
DOI: 10.1136/bmj-2026-100749 ↗Kurz gefasst
Editorial in der Zeitschrift BMJ, online erschienen am 21.09.2026. Verfasst von Maximilian Siebert und 1 weiteren Autor:innen. Beteiligte Einrichtung: Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, MA, USA Maximilian_siebert@hms.harvard.edu. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Better recording of dissent within licensing committees would clarify evidentiary uncertainty
Autor:innen und Institutionen
- Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, MA, USA Maximilian_siebert@hms.harvard.edu.
- Program On Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Zitieren
APA
Siebert, M., & Tibau, A. (2026). Improving transparency of drug regulatory decisions. BMJ, 394, e100749. https://doi.org/10.1136/bmj-2026-100749
Vancouver
Siebert M, Tibau A. Improving transparency of drug regulatory decisions. BMJ. 2026;394:e100749. doi:10.1136/bmj-2026-100749
BibTeX
@article{Siebert2026,
author = {Siebert, Maximilian and Tibau, Ariadna},
title = {Improving transparency of drug regulatory decisions},
journal = {BMJ},
year = {2026},
volume = {394},
pages = {e100749},
doi = {10.1136/bmj-2026-100749}
}
EUVIMED